Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) in a research report issued on Saturday. The firm set a "hold" rating on the biopharmaceutical company's stock.

ITCI has been the subject of several other reports. Cantor Fitzgerald raised Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, January 14th. Royal Bank of Canada restated a "sector perform" rating and issued a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. JPMorgan Chase & Co. lifted their price objective on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an "overweight" rating in a research report on Monday, November 4th. Piper Sandler reiterated a "neutral" rating and issued a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Finally, Needham & Company LLC restated a "hold" rating and set a $100.00 target price on shares of Intra-Cellular Therapies in a research note on Monday, January 13th. Nine analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $103.62.

Intra-Cellular Therapies Stock Performance

NASDAQ ITCI traded up $0.44 during trading hours on Friday, reaching $127.56. 1,569,131 shares of the company's stock were exchanged, compared to its average volume of 4,738,316. The company has a market capitalization of $13.56 billion, a price-to-earnings ratio of -146.62 and a beta of 0.72. The company's 50-day moving average is $102.37 and its two-hundred day moving average is $86.66. Intra-Cellular Therapies has a one year low of $62.78 and a one year high of $128.00.

Insider Transactions at Intra-Cellular Therapies

In other news, CEO Sharon Mates sold 51,000 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total value of $4,375,800.00. Following the completion of the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at approximately $91,834,228.20. This represents a 4.55 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.60% of the company's stock.

Hedge Funds Weigh In On Intra-Cellular Therapies

Institutional investors and hedge funds have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. grew its holdings in Intra-Cellular Therapies by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company's stock worth $1,878,000 after acquiring an additional 2,157 shares during the last quarter. Barclays PLC grew its stake in shares of Intra-Cellular Therapies by 282.0% in the third quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company's stock worth $2,521,000 after purchasing an additional 25,435 shares during the last quarter. Oak Ridge Investments LLC increased its holdings in Intra-Cellular Therapies by 74.1% in the fourth quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company's stock valued at $1,656,000 after purchasing an additional 8,440 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in Intra-Cellular Therapies by 31.9% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 454,538 shares of the biopharmaceutical company's stock valued at $33,258,000 after purchasing an additional 109,892 shares during the period. Finally, Principal Financial Group Inc. raised its position in Intra-Cellular Therapies by 3.3% during the 3rd quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company's stock worth $43,735,000 after purchasing an additional 18,865 shares during the last quarter. Institutional investors and hedge funds own 92.33% of the company's stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.